Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Low dose Btk inhibitors selectively block platelet activation by CLEC-2.

Nicolson PLR, Nock SH, Hinds J, Garcia-Quintanilla L, Smith CW, Campos J, Brill A, Pike JA, Khan AO, Poulter NS, Kavanagh DM, Watson S, Watson CN, Clifford H, Huissoon AP, Pollitt AY, Eble JA, Pratt G, Watson SP, Hughes CE.

Haematologica. 2020 Jan 16. pii: haematol.2019.218545. doi: 10.3324/haematol.2019.218545. [Epub ahead of print]

2.

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.

Nicolson PLR, Hughes CE, Watson S, Nock SH, Hardy AT, Watson CN, Montague SJ, Clifford H, Huissoon AP, Malcor JD, Thomas MR, Pollitt AY, Tomlinson MG, Pratt G, Watson SP.

Haematologica. 2018 Dec;103(12):2097-2108. doi: 10.3324/haematol.2018.193391. Epub 2018 Jul 19.

3.

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.

Bye AP, Unsworth AJ, Desborough MJ, Hildyard CAT, Appleby N, Bruce D, Kriek N, Nock SH, Sage T, Hughes CE, Gibbins JM.

Blood Adv. 2017 Dec 12;1(26):2610-2623. doi: 10.1182/bloodadvances.2017011999. eCollection 2017 Dec 12. Erratum in: Blood Adv. 2018 Dec 11;2(23):3515.

Supplemental Content

Support Center